Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
M1 Pram P037 in Type 1 Diabetes
NCT04816890Phase 2Completed
- Sponsor
- Adocia
- Start
- Mar 2021
- Primary completion
- Feb 2022
- Modality
- Peptides, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of ADO09 in type 1 diabetes mellitus (T1D) (2 arms), sponsored by Adocia. Primary endpoint: Body weight change from baseline to week 16 of treatment. Started Mar 2021; status: completed.
02
Drugs
ADO09
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT04816890.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04816890.